AlOraibi Sahar, Taurin Sebastien, Alshammary Sfoug
Molecular Medicine Department, Princess Al Jawhara Center for Molecular Medicine, Genetics, and Hereditary Diseases, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain.
Stem Cells Cloning. 2024 Dec 5;17:41-58. doi: 10.2147/SCCAA.S481072. eCollection 2024.
Biobanking has emerged as a transformative concept in advancing the medical field, particularly with the exponential growth of umbilical cord (UC) biobanking in recent decades. UC blood and tissue provide a rich source of primitive hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) for clinical transplantation, offering distinct advantages over alternative adult stem cell sources. However, to fully realize the therapeutic potential of UC-derived stem cells and establish a comprehensive global UC-biobanking network, it is imperative to optimize and standardize UC processing, cryopreservation methods, quality control protocols, and regulatory frameworks, alongside developing effective consent provisions. This review aims to comprehensively explore recent advancements in UC biobanking, focusing on the establishment of rigorous safety and quality control procedures, the standardization of biobanking operations, and the optimization and automation of UC processing and cryopreservation techniques. Additionally, the review examines the expanded clinical applications of UC stem cells, addresses the challenges associated with umbilical cord biobanking and UC-derived stem cell therapies, and discusses the promising role of artificial intelligence (AI) in enhancing various operational aspects of biobanking, streamlining data processing, and improving data analysis accuracy while ensuring compliance with safety and quality standards. By addressing these critical areas, this review seeks to provide insights into the future direction of UC biobanking and its potential to significantly impact regenerative medicine.
生物样本库已成为推进医学领域发展的一个变革性概念,尤其是近几十年来脐带生物样本库呈指数级增长。脐带血和组织为临床移植提供了丰富的原始造血干细胞(HSCs)和间充质干细胞(MSCs)来源,相较于其他成体干细胞来源具有明显优势。然而,为了充分实现脐带源干细胞的治疗潜力并建立一个全面的全球脐带生物样本库网络,必须优化和规范脐带处理、冷冻保存方法、质量控制方案及监管框架,同时制定有效的知情同意条款。本综述旨在全面探讨脐带生物样本库的最新进展,重点关注严格的安全和质量控制程序的建立、生物样本库操作的标准化以及脐带处理和冷冻保存技术的优化与自动化。此外,该综述还研究了脐带干细胞扩展的临床应用,解决了与脐带生物样本库及脐带源干细胞疗法相关的挑战,并讨论了人工智能(AI)在加强生物样本库各个操作环节、简化数据处理以及提高数据分析准确性同时确保符合安全和质量标准方面的前景作用。通过探讨这些关键领域,本综述旨在为脐带生物样本库的未来发展方向及其对再生医学产生重大影响的潜力提供见解。